Research
Evidence, read off the primary source.
No pattern-matched citations and no PMIDs pulled from memory. Every regulatory date, study, and label quote below was checked against its primary source before publication — see each article's reference list. 134 articles published so far.
How we verify a source
A PubMed citation is checked against PubMed's own record, not typed from recall. A regulatory page is read at the source and quoted, not paraphrased from a secondary blog. If a claim cannot be verified this way, it is softened or removed — never guessed.
Filter by topic
Showing 1–24 of 134 articles
Evidence review
503A vs. 503B Pharmacy: What It Means for Your Compounded GLP-1 or Peptide
A 503A pharmacy compounds for one patient's prescription; a 503B facility is FDA-registered and held to drug-manufacturing rules. What it means for you.
ReadEvidence review
Cheapest GLP-1 Without Insurance (2026): Every Compounded and Brand Cash Price, Compared
Compounded semaglutide from $69/mo and tirzepatide from $119/mo as a plain monthly rate, beside Wegovy and Zepbound cash prices.
ReadEvidence review
Sermorelin vs. Ipamorelin vs. CJC-1295: What the Evidence on Growth-Hormone Secretagogues Actually Shows
Sermorelin vs ipamorelin vs CJC-1295: two share a receptor, one doesn't. None is FDA-approved for what telehealth sells, and all three are banned in sport.
ReadEvidence review
BPC-157 Dosage: What Studies Actually Used — Not a Recommendation
BPC-157 has no FDA-approved dose or human trial that established one. Here's what animal studies and small human pilots actually administered — not advice.
ReadEvidence review
CJC-1295: What the Evidence Actually Shows
CJC-1295 IS the albumin-binding DAC modification — the compound's defining feature. What its discovery paper and human trial actually show.
ReadEvidence review
Does Ozempic Cause Hair Loss? What the Research Actually Shows
A 2026 meta-analysis found a real hair-loss risk on GLP-1 drugs — but the honest mechanism looks like rapid weight loss itself, not the drug directly.
ReadEvidence review
GLOW Peptide Blend: What the Evidence Shows
GLOW combines GHK-Cu, BPC-157, and TB-500 in one vial. No trial has tested the combination — here's what each component's own evidence actually shows.
ReadEvidence review
GLP-1 Drugs and Muscle Loss: What the DXA Data Show
About a quarter of the weight lost on a GLP-1 is lean tissue. The trials that measured it also found the same ratio in their placebo arms.
ReadEvidence review
How Much Do Peptides Cost? 2026 Monthly Prices for Sermorelin, NAD+, GHK-Cu, PT-141 and GLP-1s
Median monthly prices from 520 telehealth listings run $149 to $259 by compound. Ranges, what's included, and how to spot a teaser price.
ReadEvidence review
Ipamorelin vs. Sermorelin: What the Evidence Actually Shows
Ipamorelin vs sermorelin: different receptors, and a real evidence gap. Sermorelin has decades of trial data; ipamorelin has one missed-endpoint trial.
ReadEvidence review
Is NAD+ a Peptide? What It Actually Is, and Why the Label Matters
No. NAD+ is a dinucleotide coenzyme with a phosphate backbone — no amino acids, no peptide bonds. Here's the formula, and why the distinction matters.
ReadEvidence review
Retatrutide Dosing: The Doses and Titration Schedules Actually Tested in Its Clinical Trials
Retatrutide has no FDA-approved dose. Here is the titration schedule and dose arms its own phase 2 and phase 3 trials actually used — not dosing advice.
ReadEvidence review
Retatrutide: What's Actually Approved, What's Actually Known, and What It Actually Costs Right Now
Retatrutide has no FDA approval and no legal purchase pathway — what "buy retatrutide" searches actually find, and what's available today.
ReadEvidence review
Semaglutide Dosage Chart: What the Wegovy and Ozempic Labels Actually Specify
The semaglutide dosage chart, off the Wegovy and Ozempic labels: two different ladders, the 7.2 mg tier, tablets, missed doses, and the mg/mL conversion.
ReadEvidence review
Semaglutide Side Effects: What Wegovy and Ozempic Report
Semaglutide has two FDA labels reporting different rates for the same molecule. What Wegovy and Ozempic actually say, and why they disagree.
ReadEvidence review
Sermorelin vs. Tesamorelin: What the Evidence and FDA Approval Actually Show
Tesamorelin has one narrow FDA-approved use; sermorelin's own approval was pediatric and is discontinued. No trial compares them directly.
ReadEvidence review
TB-500: What the Evidence Actually Shows
TB-500 is marketed as thymosin beta-4, but it is a different synthetic fragment with almost no human data of its own. Here is what the evidence shows.
ReadEvidence review
Do Peptides Show Up on a Drug Test? Employment Panels, WADA and Military Rules
Not on a standard workplace panel. Sermorelin, tesamorelin, ipamorelin, BPC-157 and TB-500 are banned in sport at all times; GLP-1s are not. Here's the detail.
ReadEvidence review
Compounded Tirzepatide or Semaglutide "With B12" (or B6): What the Additive Does and Doesn't Do
Why compounded GLP-1s come with B12, B6 or glycine, what FDA and Lilly have said, whether it helps with nausea, and whether sellers charge more for it.
ReadEvidence review
GHK-Cu Before and After: What Injections and Creams Can (and Can't) Change
Two small human trials tested GHK-Cu on skin; neither beat its comparator. Injected GHK-Cu has no human before-and-after data. What to expect and what it costs.
ReadEvidence review
How Long Does Compounded Tirzepatide or Semaglutide Last in the Fridge? (And Does It Expire?)
Until the beyond-use date on your vial's label, set by the pharmacy that made it. What the Zepbound and Wegovy labels allow, and when to throw a vial out.
ReadEvidence review
IGF-1 LR3: What the Evidence Actually Shows
IGF-1 LR3 was engineered as a lab reagent, not a drug candidate. Here's what its 1992 discovery paper actually says, and why no human trial exists.
ReadEvidence review
NAD+ Injections Before and After: Energy, Sleep, Skin — What the Studies Show
No trial has measured energy, sleep or skin after NAD+ injections. What the human studies did measure, the side effects they found, and what a month costs.
ReadEvidence review
NAD+: What the Evidence Actually Shows
NAD+ has a large basic-science literature and almost no human outcome trials of the injectable product actually sold. Here's what the trial record shows.
Read
Nothing matches these filters
No article matches both the search text and the topic selected. Try clearing one of the two filters.